By Jeffrey T. Lewis

AC Immunity's shares rose 18% after the biopharmaceutical company got fast-track designation for a treatment for Alzheimer's Disease from the Food and Drug Administration.

Shares reached $2.33 in pre-market trading and were down 3% from the end of last year through Monday's close.

The company said Tuesday before trading began that its anti-amyloid beta active immunotherapy-candidate, ACI-24.060, got the designation, which is intended to speed up the development and review of drugs that treat serious conditions and fill an unmet medical need.

The goal of the designation is to speed important new drugs through the approval process and get them to patients as quickly as possible, according to the FDA

Write to Jeffrey T. Lewis at jeffrey.lewis@wsj.com

(END) Dow Jones Newswires

June 27, 2023 07:56 ET (11:56 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni AC Immune (NASDAQ:ACIU)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di AC Immune
Grafico Azioni AC Immune (NASDAQ:ACIU)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di AC Immune